Next Article in Journal
Transcriptional and Post-Translational Regulation of Junctional Adhesion Molecule-B (JAM-B) in Leukocytes under Inflammatory Stimuli
Next Article in Special Issue
RNA Editing Enzyme ADAR1 Regulates METTL3 in an Editing Dependent Manner to Promote Breast Cancer Progression via METTL3/ARHGAP5/YTHDF1 Axis
Previous Article in Journal
Nanomaterials Used in Fluorescence Polarization Based Biosensors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 15
10.3390/ijms23158645
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells

Int. J. Mol. Sci. 2022, 23(15), 8645; https://doi.org/10.3390/ijms23158645
by Ji Yoon Kim 1, Seung Yoon Han 1, Jung Yoo 1, Go Woon Kim 1, Yu Hyun Jeon 1, Sang Wu Lee 1, Jongsun Park 2,3 and So Hee Kwon 1,*
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(15), 8645; https://doi.org/10.3390/ijms23158645
Submission received: 14 June 2022 / Revised: 27 July 2022 / Accepted: 30 July 2022 / Published: 3 August 2022
(This article belongs to the Special Issue Epigenetic and Transcriptional Mechanisms in Gynecologic Cancers Development, Progression, and Resistance to Treatment)

Round 1

Reviewer 1 Report

Dear Editor

I have revised the work: HDAC8-selective Inhibition by PCI-34051 Enhances Anticancer Effects of ACY-241 in Ovarian Cancer Cells which is very interesting, however, I have some suggestions

1.- It is not clear why the PCI-34051 effectively suppresses cell proliferation in wild-type p53 than on mutant protein. 

2.- I suggest to include some anti-ovarian cancer drugs reported elsewhere to compare the these HDAC inhibitors tested.

3.- Due to there are pan-HDAC inhibitors, I suggest to include one of this, particularly, one that target HDAC6 and HDAC8, ej. droxinostat.

4.- It is not clear why the authors select as target HDAC6 and HDAC8 due to there are other HDAC overexpresed in ovarian cancer: https://m.ejgo.org/Synapse/Data/PDFData/1114JGO/jgo-19-185.pdf, https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0855-4

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

In this study, Kim et al. show that inhibition of HDAC8 acts synergistically with HDAC6 inhibition in p53 wild type ovarian cancer cell lines. The results are clear and relevant, although the conclusions can only be applied to cell lines.

The authors should include experiments showing the effect of ACY-241 and PCI-34051 in p53 mutant cell lines, looking at cell proliferation and viability.

The effects seem to be more marked in TOV-21G than in A2780, despite both cell lines being p53 wild type. Do the authors have any explanation for those differences?

As a general comment, the font size in the figures is small. It should be changed to increase the readability of the manuscript.

 

 

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Dear Editor

I have revised the replay response and the final article’s version. I suggest to add

references  to support your responses in case of no including experimental assays. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors have addressed all my comments. I recommend publication of the article.

Author Response

We thank the reviewer for recognizing and reviewing the potential importance of our findings.

Back to TopTop